FdaApplication
NDA 020762
Identifiers
- fda_app_no: NDA020762
Properties
| Property | Value |
|---|---|
| applicant_name | ORGANON LLC |
| application_type | NDA |
| approval_date | 1997-10-01 |
Revenue by product
NASONEX
| Period | Revenue |
|---|---|
| Q2 2026 | $58.0M |
| Q1 2026 | $65.0M |
| Q4 2025 | $65.0M |
| Q3 2025 | $60.0M |
| Q2 2025 | $66.0M |
| Q1 2025 | $72.0M |
| Q4 2024 | $76.0M |
| Q3 2024 | $63.0M |
| Q2 2024 | $60.0M |
| Q1 2024 | $77.0M |
| Q4 2023 | $65.0M |
| Q3 2023 | $55.0M |
| Q2 2023 | $66.0M |
| Q1 2023 | $71.0M |
| Q4 2022 | $56.0M |
| Q3 2022 | $49.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NASONEX | MOMETASONE FUROATE | 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SPRAY, METERED;NASAL |
1 product